ArticleNPJ digital medicine2026
Computational pharmacovigilance of Lifitegrast in dry eye disease using machine learning and network toxicology.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-database pharmacovigilance identifies disproportionate reporting of hepatobiliary events with avacopan: an integrative study with network pharmacology and interpretable machine learning.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events.Frontiers in pharmacology · 2026Article
- Computational pharmacovigilance of tranexamic acid: implications for intracerebral hemorrhage based on FAERS database and network toxicology.Frontiers in pharmacology · 2026Article
- Comparative real-world safety profiles of caspofungin, micafungin, and anidulafungin: a disproportionality analysis based on FAERS and VigiAccess databases.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lifitegrast, as a novel therapeutic agent for dry eye disease (DED), has garnered considerable clinical attention, yet the prediction and risk assessment of its adverse drug events (ADEs) remain methodologically challenging. This investigation seeks to establish a comprehensive predictive framework for Lifitegrast ADEs and evaluate therapeutic risks through advanced computational pharmacovigilance methodologies. Utilizing the FDA Adverse Event Reporting System (FAERS) database (2016Q1-2024Q4), we constructed a multi-tiered ADE prediction framework incorporating statistical learning algorithms and network toxicology approaches. Neural network architectures were employed to analyze drug-gene interaction networks, computational linguistics techniques were utilized to extract adverse reaction patterns, and ensemble learning methodologies were implemented to optimize risk prediction accuracy. An automated risk assessment platform was developed to facilitate personalized medication safety surveillance. Analysis encompassed 4511 reports, with the constructed computational prediction model demonstrating superior performance in ADE identification (AUC = 0.892, accuracy = 0.847). Advanced algorithms successfully identified 16 significant ADE signals, including instillation site pain and dysgeusia. Network toxicology analysis established ICAM1, MMP9, and SRC as critical regulatory genes. Neural network models effectively predicted drug-target interactions, with molecular docking validation confirming strong binding affinities (binding energy < -9 kcal/mol). The developed automated risk assessment platform enables real-time monitoring and personalized risk stratification. This study established a computationally-enhanced Lifitegrast safety assessment framework, providing innovative methodological solutions for pharmacovigilance and precision medicine, substantially advancing the sophistication of drug safety monitoring systems.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.